Inicio › Leucemia linfocítica crónica › Míchigan

Ensayos clínicos de Leucemia linfocítica crónica en Míchigan

12 estudios sobre Leucemia linfocítica crónica buscan participantes en Míchigan.

Ciudades en Míchigan

Texto oficial del estudio (inglés)

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
Bronson Battle Creek, Battle Creek
Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
y 43 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT04269902

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

The Cancer and Hematology Centers, Grand Rapids

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT06943872

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

Karmanos Cancer Institute, Detroit

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT05006716

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Karmanos Cancer Institute, Detroit

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT06973187

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

Corewell Health the Michigan Cancer Consortium, Grand Rapids

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT06846671

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Corewell Health-Lemmon Holton Cancer Pavilion ( Site 0011), Grand Rapids

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 24 sept 2026 · NCT06136559

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Karmanos Cancer Center, Detroit

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 17 sept 2026 · NCT07221500

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
y 4 más

ReclutandoFase 3

Edades de 65 en adelante · Todos los sexos · Actualizado el 2 sept 2026 · NCT07321652

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

MyMichigan Medical Center Gratiot, Alma
MyMichigan Medical Center Alpena, Alpena
Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
y 71 más

ReclutandoEstudio observacionalSe aceptan voluntarios sanos

Edades de 40 a 75 · Todos los sexos · Actualizado el 2 sept 2026 · NCT05334069

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

West Michigan Cancer Center, Kalamazoo

ReclutandoEstudio observacional

Edades de 18 en adelante · Todos los sexos · Actualizado el 7 may 2026 · NCT02269592

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Henry Ford Hospital /ID# 270973, Detroit

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 9 abr 2026 · NCT06428019

HPC Offered for PRESERVE Expansion

Henry Ford Health, Detroit

ReclutandoEstudio observacional

Edades de 12 a 80 · Todos los sexos · Actualizado el 28 ago 2025 · NCT07145411

De ClinicalTrials.gov, datos obtenidos el 1 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.